Sana Biotechnology, Inc. (SANA)

NASDAQ: SANA · IEX Real-Time Price · USD
9.94
+1.49 (17.63%)
At close: Feb 27, 2024, 4:00 PM
10.05
+0.11 (1.11%)
After-hours: Feb 27, 2024, 7:51 PM EST
17.63%
Market Cap 2.17B
Revenue (ttm) n/a
Net Income (ttm) -275.58M
Shares Out 218.99M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,358,255
Open 8.53
Previous Close 8.45
Day's Range 8.49 - 10.00
52-Week Range 2.75 - 10.00
Beta 1.25
Analysts Strong Buy
Price Target 9.33 (-6.14%)
Earnings Date Mar 14, 2024

About SANA

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); S... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 421
Stock Exchange NASDAQ
Ticker Symbol SANA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SANA stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is a decrease of -6.14% from the latest price.

Price Target
$9.33
(-6.14% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence withou...

14 days ago - GlobeNewsWire

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has closed...

15 days ago - GlobeNewsWire

Sana Biotechnology Announces Pricing of Upsized Public Offering

SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced...

19 days ago - GlobeNewsWire

Sana Biotechnology Announces Proposed Public Offering of Common Stock

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has commen...

20 days ago - GlobeNewsWire

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and ...

7 weeks ago - GlobeNewsWire

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...

7 weeks ago - GlobeNewsWire

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission

2 months ago - GlobeNewsWire

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in...

3 months ago - GlobeNewsWire

Sana Biotechnology to Present at November and December 2023 Investor Conferences

SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...

3 months ago - GlobeNewsWire

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

Goal is to report UP421 proof of concept data in 2023 and 2024 Potential to remove immunosuppression from islet cell transplantation SEATTLE, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc....

3 months ago - GlobeNewsWire

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

Enrolling Phase 1 ARDENT trial investigating SC291 in patients with refractory B-cell malignancies with initial data expected in 2023 and more robust data in 2024

3 months ago - GlobeNewsWire

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstract...

4 months ago - GlobeNewsWire

Sana Biotechnology will lay off 29% of workforce

Sana Biotechnology will reduce its workforce by 29%, the Seattle-based cell and gene therapy company revealed in a SEC filing Tuesday.

5 months ago - GeekWire

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection

5 months ago - GlobeNewsWire

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Developmen...

Other symbols: DNLIFHTXMCRBMRNAOMGA
6 months ago - PRNewsWire

Sana Biotechnology to Present at September 2023 Investor Conferences

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...

6 months ago - GlobeNewsWire

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year

7 months ago - GlobeNewsWire

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million ...

Other symbols: DNLIFHTXMCRBMRNAOMGA
8 months ago - PRNewsWire

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression

9 months ago - GlobeNewsWire

Sana Biotechnology to Present at June 2023 Investor Conferences

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas...

9 months ago - GlobeNewsWire

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model

10 months ago - GlobeNewsWire

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year

10 months ago - GlobeNewsWire

Sana Biotechnology to Present at May 2023 Investor Conferences

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas...

10 months ago - GlobeNewsWire

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that six abstracts ...

10 months ago - GlobeNewsWire

Sana Biotechnology to Host Research & Development Day

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that management w...

11 months ago - GlobeNewsWire